{
    "clinical_study": {
        "@rank": "70499", 
        "arm_group": {
            "arm_group_label": "Bimatoprost 0.01%", 
            "arm_group_type": "Experimental", 
            "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate bimatoprost 0.01% (LUMIGAN\u00ae RC) in patients with elevated\n      intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension\n      (OHT) in a clinical setting."
        }, 
        "brief_title": "A Study of LUMIGAN\u00ae RC in the Clinical Setting", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                        "title": "Bimatoprost 0.01%"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "1137"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "12.7", 
                                            "@value": "66.7"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "605"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "532"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Naive patients did not use glaucoma medication prior to study entry.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "460"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "32.2"
                                                    }
                                                }, 
                                                "sub_title": "0 (none)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "39.8"
                                                    }
                                                }, 
                                                "sub_title": "+0.5 (trace)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "21.3"
                                                    }
                                                }, 
                                                "sub_title": "+1 (mild)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "5.9"
                                                    }
                                                }, 
                                                "sub_title": "+2 (moderate)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0.9"
                                                    }
                                                }, 
                                                "sub_title": "+3 (severe)"
                                            }
                                        ]
                                    }, 
                                    "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Naive patients did not use glaucoma medication prior to study entry.", 
                                    "param": "Number", 
                                    "title": "Percentage of Treatment-Naive Patients With Ocular Hyperemia", 
                                    "units": "Percentage of Patients"
                                }
                            ]
                        }, 
                        "population": "All patients who were consented and completed the Baseline visit, and who had data for Week 12", 
                        "safety_issue": "No", 
                        "time_frame": "Week 12", 
                        "title": "Percentage of Treatment-Naive Patients With Ocular Hyperemia", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "IOP is a measurement of the fluid pressure inside the eye. Naive patients did not use glaucoma medication prior to study entry. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "522"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "15.4", 
                                                    "@value": "-30.9"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "IOP is a measurement of the fluid pressure inside the eye. Naive patients did not use glaucoma medication prior to study entry. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Percent Change From Baseline in Intraocular Pressure (IOP) in the Study Eye of Treatment-Naive Patients", 
                                    "units": "Percent Change"
                                }
                            ]
                        }, 
                        "population": "Intent to Treat: all patients who were consented and completed the Baseline visit", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, 12 Weeks", 
                        "title": "Percent Change From Baseline in Intraocular Pressure (IOP) in the Study Eye of Treatment-Naive Patients", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "IOP is a measurement of the fluid pressure inside the eye. Previously treated patients used glaucoma medication prior to study entry and were switched from their previous therapy to study treatment. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "450"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "18.8", 
                                                    "@value": "-16.1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "IOP is a measurement of the fluid pressure inside the eye. Previously treated patients used glaucoma medication prior to study entry and were switched from their previous therapy to study treatment. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Percent Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients", 
                                    "units": "Percent Change"
                                }
                            ]
                        }, 
                        "population": "Intent to Treat: all patients who were consented and completed the Baseline visit", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, 12 Weeks", 
                        "title": "Percent Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "IOP is a measurement of the fluid pressure inside the eye. Previously treated patients used glaucoma medication prior to study entry and added study treatment as adjunctive therapy. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "165"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "20.4", 
                                                    "@value": "-16.1"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "IOP is a measurement of the fluid pressure inside the eye. Previously treated patients used glaucoma medication prior to study entry and added study treatment as adjunctive therapy. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Percent Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy", 
                                    "units": "Percent Change"
                                }
                            ]
                        }, 
                        "population": "Intent to Treat: all patients who were consented and completed the Baseline visit", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, 12 Weeks", 
                        "title": "Percent Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "522"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "5.8", 
                                                        "@value": "23.5"
                                                    }
                                                }, 
                                                "sub_title": "Baseline"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.9", 
                                                        "@value": "-7.4"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline at Week 6"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.9", 
                                                        "@value": "-7.7"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline at Week 12"
                                            }
                                        ]
                                    }, 
                                    "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in IOP in the Study Eye of Treatment-Naive Patients", 
                                    "units": "Millimeters of Mercury (mmHg)"
                                }
                            ]
                        }, 
                        "population": "Intent to Treat: all patients who were consented and completed the Baseline visit", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 6, Week 12", 
                        "title": "Change From Baseline in IOP in the Study Eye of Treatment-Naive Patients", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "450"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.6", 
                                                        "@value": "20.3"
                                                    }
                                                }, 
                                                "sub_title": "Baseline"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.3", 
                                                        "@value": "-3.5"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline at Week 6"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.3", 
                                                        "@value": "-3.7"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline at Week 12"
                                            }
                                        ]
                                    }, 
                                    "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients", 
                                    "units": "Millimeters of Mercury (mmHg)"
                                }
                            ]
                        }, 
                        "population": "Intent to Treat: all patients who were consented and completed the Baseline visit", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 6, Week 12", 
                        "title": "Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "165"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "5.2", 
                                                        "@value": "20.8"
                                                    }
                                                }, 
                                                "sub_title": "Baseline"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.7", 
                                                        "@value": "-3.8"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline at Week 6"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.6", 
                                                        "@value": "-3.7"
                                                    }
                                                }, 
                                                "sub_title": "Change from Baseline at Week 12"
                                            }
                                        ]
                                    }, 
                                    "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy", 
                                    "units": "Millimeters of Mercury (mmHg)"
                                }
                            ]
                        }, 
                        "population": "Intent to Treat: all patients who were consented and completed the Baseline visit", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline, Week 6, Week 12", 
                        "title": "Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Ocular adverse events are defined as any untoward medical occurrence in a patient's eye(s) during study participation, regardless of relationship to treatment.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "1137"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "3.9"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Ocular adverse events are defined as any untoward medical occurrence in a patient's eye(s) during study participation, regardless of relationship to treatment.", 
                                    "param": "Number", 
                                    "title": "Percentage of Patients Discontinuing Due to Ocular Adverse Events", 
                                    "units": "Percentage of Patients"
                                }
                            ]
                        }, 
                        "population": "Intent to Treat: all patients who were consented and completed the Baseline visit", 
                        "safety_issue": "No", 
                        "time_frame": "12 Weeks", 
                        "title": "Percentage of Patients Discontinuing Due to Ocular Adverse Events", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Previously treated patients used glaucoma medication prior to study entry and were switched from their previous therapy to study treatment.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "400"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "35.5"
                                                    }
                                                }, 
                                                "sub_title": "0 (none)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "41.0"
                                                    }
                                                }, 
                                                "sub_title": "+0.5 (trace)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "17.3"
                                                    }
                                                }, 
                                                "sub_title": "+1 (mild)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "6.0"
                                                    }
                                                }, 
                                                "sub_title": "+2 (moderate)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0.3"
                                                    }
                                                }, 
                                                "sub_title": "+3 (severe)"
                                            }
                                        ]
                                    }, 
                                    "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Previously treated patients used glaucoma medication prior to study entry and were switched from their previous therapy to study treatment.", 
                                    "param": "Number", 
                                    "title": "Percentage of Previously Treated (Switched) Patients With Ocular Hyperemia", 
                                    "units": "Percentage of Patients"
                                }
                            ]
                        }, 
                        "population": "All patients who were consented and completed the Baseline visit, and who had data for Week 12", 
                        "safety_issue": "No", 
                        "time_frame": "Week 12", 
                        "title": "Percentage of Previously Treated (Switched) Patients With Ocular Hyperemia", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Previously treated patients used glaucoma medication prior to study entry and added study treatment as adjunctive therapy.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                                "title": "Bimatoprost 0.01%"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "141"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "28.4"
                                                    }
                                                }, 
                                                "sub_title": "0 (none)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "36.9"
                                                    }
                                                }, 
                                                "sub_title": "+0.5 (trace)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "24.1"
                                                    }
                                                }, 
                                                "sub_title": "+1 (mild)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "9.2"
                                                    }
                                                }, 
                                                "sub_title": "+2 (moderate)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1.4"
                                                    }
                                                }, 
                                                "sub_title": "+3 (severe)"
                                            }
                                        ]
                                    }, 
                                    "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Previously treated patients used glaucoma medication prior to study entry and added study treatment as adjunctive therapy.", 
                                    "param": "Number", 
                                    "title": "Percentage of Patients Treated With Adjunctive Therapy With Ocular Hyperemia", 
                                    "units": "Percentage of Patients"
                                }
                            ]
                        }, 
                        "population": "All patients who were consented and completed the Baseline visit, and who had data for Week 12", 
                        "safety_issue": "No", 
                        "time_frame": "Week 12", 
                        "title": "Percentage of Patients Treated With Adjunctive Therapy With Ocular Hyperemia", 
                        "type": "Primary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                        "title": "Bimatoprost 0.01%"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1137", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "997", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "140", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "clinicaltrials@allergan.com", 
                "name_or_title": "Vice President  Medical Affairs,", 
                "organization": "Allergan, Inc", 
                "phone": "714-246-4500"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
                        "title": "Bimatoprost 0.01%"
                    }
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "3", 
                                            "@subjects_at_risk": "1137"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "1137"
                                            }, 
                                            "sub_title": "Cerebrovascular Accident"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "1137"
                                            }, 
                                            "sub_title": "Myocardial Infarction"
                                        }
                                    ]
                                }, 
                                "title": "Cardiac disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "assessment": "Non-systematic Assessment", 
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "1137"
                                        }, 
                                        "sub_title": "Malaise"
                                    }
                                }, 
                                "title": "General disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "default_vocab": "MedDRA version 14.0"
                }
            }
        }, 
        "completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Glaucoma, Primary Open Angle", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension", 
                "Glaucoma, Open-Angle"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Elevated IOP due to either primary open-angle glaucoma or ocular hypertension\n\n          -  Determined by the treating physician to require treatment with LUMIGAN\u00ae RC\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1137", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "firstreceived_results_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01833741", 
            "org_study_id": "CLEAR"
        }, 
        "intervention": {
            "arm_group_label": "Bimatoprost 0.01%", 
            "description": "Bimatoprost 0.01% (LUMIGAN\u00ae RC) administered as one drop in the study eye(s) each evening for 12 weeks.", 
            "intervention_name": "Bimatoprost 0.01%", 
            "intervention_type": "Drug", 
            "other_name": "LUMIGAN\u00ae RC"
        }, 
        "intervention_browse": {
            "mesh_term": "Bimatoprost"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Barrie", 
                    "country": "Canada", 
                    "state": "Ontario"
                }
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Naive patients did not use glaucoma medication prior to study entry.", 
                "measure": "Percentage of Treatment-Naive Patients With Ocular Hyperemia", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Previously treated patients used glaucoma medication prior to study entry and were switched from their previous therapy to study treatment.", 
                "measure": "Percentage of Previously Treated (Switched) Patients With Ocular Hyperemia", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia is graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness). Previously treated patients used glaucoma medication prior to study entry and added study treatment as adjunctive therapy.", 
                "measure": "Percentage of Patients Treated With Adjunctive Therapy With Ocular Hyperemia", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01833741"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "IOP is a measurement of the fluid pressure inside the eye. Naive patients did not use glaucoma medication prior to study entry. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                "measure": "Percent Change From Baseline in Intraocular Pressure (IOP) in the Study Eye of Treatment-Naive Patients", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "description": "IOP is a measurement of the fluid pressure inside the eye. Previously treated patients used glaucoma medication prior to study entry and were switched from their previous therapy to study treatment. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                "measure": "Percent Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "description": "IOP is a measurement of the fluid pressure inside the eye. Previously treated patients used glaucoma medication prior to study entry and added study treatment as adjunctive therapy. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                "measure": "Percent Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                "measure": "Change From Baseline in IOP in the Study Eye of Treatment-Naive Patients", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6, Week 12"
            }, 
            {
                "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                "measure": "Change From Baseline in IOP in the Study Eye of Previously Treated (Switched) Patients", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6, Week 12"
            }, 
            {
                "description": "IOP is a measurement of the fluid pressure inside the eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase (worsening).", 
                "measure": "Change From Baseline in IOP in the Study Eye of Patients Treated With Adjunctive Therapy", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 6, Week 12"
            }, 
            {
                "description": "Ocular adverse events are defined as any untoward medical occurrence in a patient's eye(s) during study participation, regardless of relationship to treatment.", 
                "measure": "Percentage of Patients Discontinuing Due to Ocular Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}